Charleston-based Argolyn Bioscience receives third patentJun. 1, 2003 Charleston Regional Business Journal
“This is a key patent for Argolyn because it is the first patent in a second series of compounds that are fundamental to our work,” says Argolyn president, Pearce Gilbert. “Although there are no guarantees, it suggests that the remaining patents in this second series will issue in due course. We are very pleased to have this one under our belts.” Argolyn has a total of six other U.S. patents currently pending, with foreign equivalents also pending in the major world markets. |
![]() |